A

Agilent Technologies Inc

A
Accountable AI Logo

Agilent Technologies Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-08

Snapshot

  • Goodwill of 4.5B is 70% of equity (6.4B) - acquisition-heavy model creates impairment risk if end markets weaken[Goodwill]
  • Operating margin TTM 21.3% vs industry median 2.4% - 9x advantage reflects pricing power in analytical instruments[Operating Margin TTM]
  • FCF TTM of 1.1B at 16% margin funds 71M dividends + buybacks with 1.5B cash buffer at 0.54 debt/equity[Free Cash Flow TTM]

Watch Triggers

  • Gross Profit 1Y Growth: Falls below 0% or accelerates above 8%Current 3.9% is tepid; deterioration signals pricing pressure, acceleration validates premium
  • Asset Impairment Charge: Any material charge (currently 0)4.5B goodwill at risk if life sciences M&A thesis fails
  • Operating Margin TTM: Drops below 18%Would signal competitive erosion in core analytical instruments

Bull Case

Premium profitability (21% op margin, 18% net margin, 20% ROE TTM) with conservative leverage (0.54 D/E) enables sustained capital returns and M&A optionality

Operating Margin TTMROE TTMDebt to Equity

FCF conversion of 73% (1.1B FCF on 1.5B operating cash flow TTM) with capex only 6% of revenue supports dividend growth

Free Cash Flow TTMCash Flow TTMCapital Expenditure TTM

Bear Case

P/B of 28.5x vs tangible book of only 1.4B - paying 40.6B market cap for 4.5B goodwill-heavy equity base

PB RatioTangible Book ValueGoodwill

Revenue of 6.8B TTM barely above industry mean (5.9B) despite premium valuation - limited scale advantage

Total Revenue TTMPS RatioPE Ratio

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
55%

Leverage A's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Margin compression likely as 3.9% gross profit growth lags R&D intensity (6.6% of revenue)

1-3ymed
  • R&D spend 447M TTM requires revenue growth to maintain margins
  • Gross profit growth 3.9% below historical norms
  • Competitive pressure in life sciences instrumentation
Gross Profit 1Y Growth: 3.9%R&D TTM: 447M (6.6% of revenue)Operating Margin TTM: 21.3%
Valuation Context
Caveats

Public Strategies Rankings

See how Agilent Technologies Inc ranks across different investment strategies.

Leverage A's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.